阿那曲唑:绝经后早期乳腺癌辅助内分泌治疗的又一选择

Anastrozole: a choice of adjuvant endocrine therapy for postmenopausal women with early breast cancer

下载PDF

导出

摘要 1文献类型治疗 2证据水平 1b 3文献来源

作者王坤杨学宁

机构地区广东省人民医院肿瘤中心乳腺科中山大学附属第三医院

出处《循证医学》 CSCD 2003年第3期155-159,共5页 The Journal of Evidence-Based Medicine

关键词阿那曲唑绝经后早期乳腺癌辅助治疗内分泌治疗 anastrozole breast neoplasms endocrine therapy

参考文献4

1[1]Buzdar A U. New generation aromatase inhibitors-from the advanced to the adjuvant setting [J]. Breast Cancer Res Treat,75(Suppp 1):S13-17
2[2]Nahboltz J M, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen a first line tberapy for advanced breast cancer in postmenopausal women: results of a North American multi-center randomized trial [J]. J Clin Oncol,2000,18(22):3758-3767
3[3]Bonnetere J, Thurliman B, Robertson J F, et al. Anastrozole versus tomoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex rancomized group efficacy and tolerability study [J]. J Clin Oncol, 2000,18(22):3748-3757
4[4]Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early tbreast cancer: an overview of the randomised trials [J].Lancet, 1998,351:1451-1467

循证医学

2003年第3期

内容加载中请稍等...